HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Miltefosine and cutaneous leishmaniasis.

AbstractPURPOSE OF REVIEW:
Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed.
RECENT FINDINGS:
Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran. Severe cutaneous leishmaniasis forms successfully treated with miltefosine are reported.
SUMMARY:
The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large-scale use in the inner regions of the endemic countries. Miltefosine also shows activity in severe or refractory cases. However, this review points out the need for further investment on clinical research into cutaneous leishmaniasis treatment.
AuthorsPaulo R L Machado, Gerson Penna
JournalCurrent opinion in infectious diseases (Curr Opin Infect Dis) Vol. 25 Issue 2 Pg. 141-4 (Apr 2012) ISSN: 1473-6527 [Electronic] United States
PMID22248979 (Publication Type: Journal Article, Review)
Chemical References
  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine
Topics
  • Administration, Oral
  • Antiprotozoal Agents (therapeutic use)
  • Clinical Trials as Topic
  • Humans
  • Leishmaniasis (drug therapy)
  • Phosphorylcholine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: